Please use this identifier to cite or link to this item:
Title: Untangling tau imaging
Austin Authors: Villemagne, Victor L ;Rowe, Christopher C ;Okamura, Nobuyuki
Affiliation: Austin Health, Heidelberg, Victoria, Australia
Molecular Imaging and Therapy
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia
Department of Medicine, The University of Melbourne, Parkville, Australia
Department of Pharmacology, Tohoku University, Sendai, Japan
Issue Date: 4-Jun-2016
Publication information: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2016; 4: 39-42
Abstract: In vivo imaging of tau deposits is providing a better understanding of the temporal and spatial tau deposition in the brain, allowing a more comprehensive insight into the causes, diagnoses, and potentially treatment of tauopathies such as Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, chronic traumatic encephalopathy, and some variants of frontotemporal lobar degeneration. The assessment of tau deposition in the brain over time will allow a deeper understanding of the relationship between tau and other variables such as cognition, genotype, and neurodegeneration, as well as assessing the role tau plays in ageing. Preliminary human studies suggest that tau imaging could also be used as a diagnostic, prognostic, and theranostic biomarker, as well as a surrogate marker for target engagement, patient recruitment, and efficacy monitoring for disease-specific therapeutic trials.
DOI: 10.1016/j.dadm.2016.05.001
ORCID: 0000-0003-3910-2453
PubMed URL:
Type: Journal Article
Subjects: PET
Tau imaging
Alzheimer's disease
Positron emission tomography
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 25, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.